2023-506555-15-00招募中1 期
First-in-human (FIH), microdosing, non-randomized, clinical trial to investigate binding of positron emission tomography tracer [68Ga]Ga-DOTA-Cys-ATH001 targeting platelet derived growth factor receptor β in healthy subjects as compared to patients with metabolic dysfunction-associated steatohepatitis (MASH) and Primary Sclerosing Cholangitis binding (PSC, liver) and patients with fibrostenotic Crohn’s disease (CD, gastrointestinal tract [GI])
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Lars Johansson
Scientific
Antaros Medical AB
研究点 (2)
Loading locations...
相似试验
已完成
不适用
A First-in-Human (FIH), Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPC5001 Administered to Healthy Subjects and Subjects with Familial Hypercholesterolemia (FH)Increased blood cholesterol levelfamilial hypercholesterolemia1002742410013317NL-OMON36203Santaris48
已完成
1 期
Testing IMM60 in combination with pembrolizumab in melanoma and non-small cell lung cancerCancerISRCTN80472712niversity of Oxford15
已完成
1 期
A first in human study to evaluate the safety and immune response to a vaccine for the treatment of a respiratory virus, when administered into the arm in healthy adult participants.Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesRespiratory Syncytial Virus InfectionACTRN12618000948291Advanced Vaccine Laboratories Pty Ltd60
招募中
1 期
A trial to assess the safety and tolerability of EBC-1013 Gel in participants with venous leg ulcers.Venous Leg UlcersSkin - Dermatological conditionsSkin - Other skin conditionsACTRN12624000544572QBiotics Group Limited35
撤回
1 期
A First-in-Human, Open-label, Phase Ia Dose Escalation Study of SON-DP in subjects with advanced/metastatic solid tumors that have relapsed or are refractory/intolerant to standard of care therapiesSolid tumor malignanciesCancer - Any cancerACTRN12623000202662Qurgen Australia Pty Ltd48